Royal Bank of Canada Reaffirms “Outperform” Rating for Shire (SHP)
SHP has been the subject of several other reports. JPMorgan Chase cut shares of Shire to a neutral rating and decreased their price objective for the company from GBX 5,000 ($69.74) to GBX 3,600 ($50.21) in a report on Tuesday, February 20th. BNP Paribas reissued an outperform rating and set a GBX 4,700 ($65.55) price objective on shares of Shire in a report on Thursday, March 22nd. Morgan Stanley decreased their price objective on shares of Shire from GBX 5,700 ($79.50) to GBX 4,700 ($65.55) and set an overweight rating for the company in a report on Monday, March 19th. Citigroup reissued a buy rating and set a GBX 5,500 ($76.71) price objective on shares of Shire in a report on Friday, January 5th. Finally, Goldman Sachs reissued a conviction-buy rating and set a GBX 4,600 ($64.16) price objective on shares of Shire in a report on Monday, March 26th. Five equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Shire has an average rating of Buy and an average price target of GBX 4,568.29 ($63.71).
SHP opened at GBX 3,894 ($54.31) on Wednesday. Shire has a twelve month low of GBX 2,940.50 ($41.01) and a twelve month high of GBX 5,021 ($70.03).
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells specialist medicines for people with rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.